Eloctate, Antihemophilic Factor receives FDA approval for treatment of Hemophilia A
The U.S. Food and Drug Administration today approved Eloctate, Antihemophilic Factor (Recombinant), Fc fusion protein, for use in adults and children who have Hemophilia A. Eloctate is the first Hemophilia A treatment More...